Symbols / BLTE Stock $158.73 -2.66% Belite Bio, Inc

Healthcare • Biotechnology • United States • NCM
BLTE (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Yu-Hsin Lin M.B.A., Ph.D.
Exch · Country NCM · United States
Market Cap 6.34B
Enterprise Value 5.75B
Income -77.61M
Sales —
FCF (ttm) -9.77M
Book/sh 19.59
Cash/sh 12.52
Employees 41
Insider 10d —
IPO Apr 29, 2022
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E 202.20
PEG —
P/S —
P/B 8.10
P/C —
EV/EBITDA -68.46
EV/Sales —
Quick Ratio 49.90
Current Ratio 50.02
Debt/Eq 0.06
LT Debt/Eq —
EPS (ttm) -2.32
EPS next Y 0.79
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-12
Earnings (prior) 2026-03-02
ROA -11.29%
ROE -16.94%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 39.97M
Shs Float 18.50M
Insider Own 44.42%
Instit Own 18.71%
Short Float 5.38%
Short Ratio 6.60
Short Interest 1.11M
52W High 200.00
vs 52W High -20.64%
52W Low 56.10
vs 52W Low 182.94%
Beta -1.22
Impl. Vol. —
Rel Volume 0.66
Avg Volume 173.97K
Volume 114.64K
Target (mean) $211.50
Tgt Median $200.50
Tgt Low $185.00
Tgt High $266.00
# Analysts 8
Recom Strong_buy
Prev Close $163.06
Price $158.73
Change -2.66%
About

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an anti-retinol-binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$211.50
Mean price target
2. Current target
$158.73
Latest analyst target
3. DCF / Fair value
$-4.40
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$158.73
Low
$185.00
High
$266.00
Mean
$211.50

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-22 reit HC Wainwright & Co. Buy → Buy $200
2026-04-13 reit HC Wainwright & Co. Buy → Buy $200
2026-03-03 main HC Wainwright & Co. Buy → Buy $200
2026-03-03 main Morgan Stanley Overweight → Overweight $201
2026-03-03 main Cantor Fitzgerald Overweight → Overweight $266
2026-01-28 reit HC Wainwright & Co. Buy → Buy $185
2026-01-26 init B of A Securities — → Buy $195
2026-01-06 init Morgan Stanley — → Overweight $191
2025-12-02 up Mizuho Neutral → Outperform $194
2025-12-01 main HC Wainwright & Co. Buy → Buy $185
2025-11-20 init Mizuho — → Neutral $105
2025-10-31 main Benchmark Buy → Buy $132
2025-09-15 main HC Wainwright & Co. Buy → Buy $98
2025-07-03 reit HC Wainwright & Co. Buy → Buy $100
2025-05-15 reit Cantor Fitzgerald Overweight → Overweight —
2025-05-15 reit HC Wainwright & Co. Buy → Buy $100
2025-03-26 reit Benchmark Buy → Buy $80
2025-03-18 reit Cantor Fitzgerald Overweight → Overweight —
2025-03-18 reit HC Wainwright & Co. Buy → Buy $100
2025-01-21 main Benchmark Buy → Buy $79
News
RSS: Latest BLTE news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-27 MATA NATHAN L. Officer — 1,000 $160.83 $162,641
2026-04-24 MATA NATHAN L. Officer — 1,000 $157.86 $159,556
2026-04-23 MATA NATHAN L. Officer — 1,000 $164.47 $166,284
2026-04-22 MATA NATHAN L. Officer — 1,000 $165.70 $170,384
2026-04-21 MATA NATHAN L. Officer — 1,000 $163.49 $166,000
2026-04-20 MATA NATHAN L. Officer — 1,000 $162.76 $163,595
2026-04-17 MATA NATHAN L. Officer — 1,000 $158.46 $161,630
2026-04-16 MATA NATHAN L. Officer — 1,000 $158.28 $160,381
2026-04-15 MATA NATHAN L. Officer — 1,000 $167.58 $168,298
2026-04-09 LIN YU-HSIN Chief Executive Officer — 9,200 $180.36 $1,669,339
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
84.21
+110.54%
40.00
+26.30%
31.67
+147.00%
12.82
Research And Development
45.38
+51.56%
29.94
+20.51%
24.84
+180.12%
8.87
Selling General And Administration
38.83
+286.11%
10.06
+47.38%
6.82
+72.67%
3.95
General And Administrative Expense
38.83
+286.11%
10.06
+47.38%
6.82
+72.67%
3.95
Other Gand A
38.83
+286.11%
10.06
+47.38%
6.82
+72.67%
3.95
Total Expenses
84.21
+110.54%
40.00
+26.30%
31.67
+147.00%
12.82
Operating Income
-84.21
-110.54%
-40.00
-26.30%
-31.67
-147.00%
-12.82
Total Operating Income As Reported
-84.21
-110.54%
-40.00
-26.30%
-31.67
-147.00%
-12.82
EBITDA
-77.14
-116.28%
-35.67
-14.33%
-31.20
-150.92%
-12.43
Normalized EBITDA
-77.14
-116.28%
-35.67
-14.33%
-31.20
-150.92%
-12.43
Reconciled Depreciation
0.46
+3.34%
0.45
+12.53%
0.40
+101.52%
0.20
EBIT
-77.61
-114.88%
-36.12
-14.30%
-31.60
-150.14%
-12.63
Net Income
-77.61
-114.73%
-36.14
-14.26%
-31.63
-150.09%
-12.65
Pretax Income
-77.61
-114.76%
-36.14
-14.28%
-31.62
-150.02%
-12.65
Net Non Operating Interest Income Expense
6.64
+78.58%
3.72
+7485.71%
0.05
+600.00%
0.01
Interest Expense Non Operating
0.00
-90.00%
0.02
-20.00%
0.03
+56.25%
0.02
Net Interest Income
6.64
+78.58%
3.72
+7485.71%
0.05
+600.00%
0.01
Interest Expense
0.00
-90.00%
0.02
-20.00%
0.03
+56.25%
0.02
Interest Income Non Operating
6.64
+77.68%
3.74
+4950.00%
0.07
+221.74%
0.02
Interest Income
6.64
+77.68%
3.74
+4950.00%
0.07
+221.74%
0.02
Other Income Expense
-0.04
-129.08%
0.14
+3625.00%
-0.00
-102.41%
0.17
Other Non Operating Income Expenses
-0.04
-129.08%
0.14
+3625.00%
-0.00
-102.41%
0.17
Tax Provision
0.00
-100.00%
0.01
-33.33%
0.01
0.00
Tax Rate For Calcs
0.00
-100.00%
0.00
+0.00%
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-77.61
-114.73%
-36.14
-14.26%
-31.63
-150.09%
-12.65
Net Income From Continuing Operation Net Minority Interest
-77.61
-114.73%
-36.14
-14.26%
-31.63
-150.09%
-12.65
Net Income From Continuing And Discontinued Operation
-77.61
-114.73%
-36.14
-14.26%
-31.63
-150.09%
-12.65
Net Income Continuous Operations
-77.61
-114.73%
-36.14
-14.26%
-31.63
-150.09%
-12.65
Normalized Income
-77.61
-114.73%
-36.14
-14.26%
-31.63
-150.09%
-12.65
Net Income Common Stockholders
-77.61
-114.73%
-36.14
-14.26%
-31.63
-150.09%
-12.65
Diluted EPS
-2.31
-95.76%
-1.18
+0.84%
-1.19
-88.89%
-0.63
Basic EPS
-2.31
-95.76%
-1.18
+0.84%
-1.19
-88.89%
-0.63
Basic Average Shares
33.54
+9.82%
30.54
+14.83%
26.59
+33.12%
19.98
Diluted Average Shares
33.54
+9.82%
30.54
+14.83%
26.59
+33.12%
19.98
Diluted NI Availto Com Stockholders
-77.61
-114.73%
-36.14
-14.26%
-31.63
-150.09%
-12.65
Line Item Trend 2025-12-31 2024-12-31 2023-12-31
Total Assets
780.56
+413.08%
152.13
+60.74%
94.64
Current Assets
494.27
+236.07%
147.07
+63.52%
89.94
Cash Cash Equivalents And Short Term Investments
492.42
+239.25%
145.15
+64.65%
88.16
Cash And Cash Equivalents
352.93
+1014.16%
31.68
-64.07%
88.16
Cash Equivalents
15.64
0.00
—
Cash Financial
337.29
+964.78%
31.68
-64.07%
88.16
Other Short Term Investments
139.49
+22.93%
113.47
0.00
Receivables
0.72
+20.88%
0.59
-31.49%
0.87
Other Receivables
0.07
—
0.82
Taxes Receivable
0.02
-5.26%
0.02
-38.71%
0.03
Accrued Interest Receivable
0.63
+10.26%
0.57
0.00
Prepaid Assets
1.13
-15.26%
1.33
+45.20%
0.92
Other Current Assets
0.01
—
—
Total Non Current Assets
286.28
+5558.90%
5.06
+7.59%
4.70
Net PPE
0.78
-19.48%
0.96
-25.83%
1.30
Gross PPE
1.28
-1.68%
1.31
-11.99%
1.48
Accumulated Depreciation
-0.51
-48.68%
-0.34
-86.34%
-0.18
Properties
0.00
0.00
0.00
Machinery Furniture Equipment
0.07
+0.00%
0.07
+17.19%
0.06
Construction In Progress
—
—
—
Other Properties
1.02
-2.11%
1.04
-15.33%
1.23
Leases
0.19
+0.00%
0.19
+0.00%
0.19
Goodwill And Other Intangible Assets
4.92
+24.02%
3.96
+20.23%
3.30
Other Intangible Assets
4.92
+24.02%
3.96
+20.23%
3.30
Investments And Advances
280.17
0.00
—
Non Current Deferred Assets
—
—
—
Non Current Prepaid Assets
0.42
+226.92%
0.13
+25.00%
0.10
Other Non Current Assets
—
—
0.06
Total Liabilities Net Minority Interest
10.07
+59.56%
6.31
+49.87%
4.21
Current Liabilities
9.88
+63.34%
6.05
+66.53%
3.63
Payables And Accrued Expenses
7.43
+55.42%
4.78
+95.26%
2.45
Payables
0.01
-61.54%
0.01
—
Current Accrued Expenses
7.43
+55.73%
4.77
+94.73%
2.45
Pensionand Other Post Retirement Benefit Plans Current
1.61
+129.02%
0.70
-3.30%
0.73
Current Debt And Capital Lease Obligation
0.24
-12.68%
0.28
-10.39%
0.31
Current Capital Lease Obligation
0.24
-12.68%
0.28
-10.39%
0.31
Other Current Liabilities
0.60
+107.27%
0.29
+93.96%
0.15
Total Non Current Liabilities Net Minority Interest
0.19
-27.97%
0.26
-54.84%
0.58
Long Term Debt And Capital Lease Obligation
0.19
-27.97%
0.26
-54.84%
0.58
Long Term Capital Lease Obligation
0.19
-27.97%
0.26
-54.84%
0.58
Preferred Securities Outside Stock Equity
—
—
—
Stockholders Equity
770.49
+428.38%
145.82
+61.25%
90.43
Common Stock Equity
770.49
+428.38%
145.82
+61.25%
90.43
Capital Stock
0.00
+33.33%
0.00
+0.00%
0.00
Common Stock
0.00
+33.33%
0.00
+0.00%
0.00
Share Issued
39.35
+23.53%
31.86
+9.16%
29.18
Ordinary Shares Number
39.34
+23.61%
31.83
+9.18%
29.15
Treasury Shares Number
0.01
-57.11%
0.03
-10.78%
0.04
Additional Paid In Capital
956.28
+276.30%
254.12
+56.57%
162.31
Retained Earnings
-185.26
-72.10%
-107.65
-50.55%
-71.50
Gains Losses Not Affecting Retained Earnings
-0.54
+18.79%
-0.66
-76.47%
-0.37
Total Equity Gross Minority Interest
770.49
+428.38%
145.82
+61.25%
90.43
Total Capitalization
770.49
+428.38%
145.82
+61.25%
90.43
Working Capital
484.39
+243.48%
141.02
+63.40%
86.31
Invested Capital
770.49
+428.38%
145.82
+61.25%
90.43
Total Debt
0.43
-20.11%
0.54
-39.39%
0.89
Capital Lease Obligations
0.43
-20.11%
0.54
-39.39%
0.89
Net Tangible Assets
765.57
+439.68%
141.86
+62.80%
87.13
Tangible Book Value
765.57
+439.68%
141.86
+62.80%
87.13
Duefrom Related Parties Current
—
0.00
-100.00%
0.02
Dueto Related Parties Current
0.01
-61.54%
0.01
0.00
Held To Maturity Securities
280.17
0.00
—
Investmentin Financial Assets
280.17
0.00
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-36.99
-26.52%
-29.23
+2.02%
-29.84
-160.40%
-11.46
Cash Flow From Continuing Operating Activities
-36.99
-26.52%
-29.23
+2.02%
-29.84
-160.40%
-11.46
Net Income From Continuing Operations
-77.61
-114.73%
-36.14
-14.26%
-31.63
-150.09%
-12.65
Depreciation Amortization Depletion
0.46
+3.34%
0.45
+12.53%
0.40
+101.52%
0.20
Depreciation
0.45
+1.57%
0.45
+11.53%
0.40
+101.52%
0.20
Amortization Cash Flow
0.01
+200.00%
0.00
0.00
0.00
Depreciation And Amortization
0.46
+3.34%
0.45
+12.53%
0.40
+101.52%
0.20
Amortization Of Intangibles
0.01
+200.00%
0.00
0.00
0.00
Other Non Cash Items
-1.31
+63.63%
-3.61
—
—
Stock Based Compensation
38.92
+333.06%
8.99
+135.08%
3.82
+157.79%
1.48
Operating Gains Losses
—
—
—
—
Unrealized Gain Loss On Investment Securities
0.00
+100.00%
-0.05
0.00
0.00
Gain Loss On Sale Of PPE
—
—
0.00
0.00
Change In Working Capital
2.55
+125.33%
1.13
+146.68%
-2.43
-394.30%
-0.49
Change In Receivables
-0.07
-189.19%
0.07
+202.78%
-0.07
-125.00%
-0.03
Change In Prepaid Assets
-0.92
+17.45%
-1.11
+68.52%
-3.53
-390.56%
-0.72
Change In Payables And Accrued Expense
3.84
+55.01%
2.48
+74.24%
1.42
+328.01%
0.33
Change In Accrued Expense
3.85
+56.15%
2.46
+73.33%
1.42
+280.97%
0.37
Change In Payable
-0.01
-161.54%
0.01
—
-0.04
Change In Other Current Liabilities
-0.30
+1.31%
-0.30
-25.00%
-0.24
-243.66%
-0.07
Investing Cash Flow
-305.11
-175.94%
-110.57
-175411.11%
-0.06
+84.01%
-0.39
Cash Flow From Continuing Investing Activities
-305.11
-175.94%
-110.57
-175411.11%
-0.06
+84.01%
-0.39
Net PPE Purchase And Sale
-0.18
-53.45%
-0.12
-84.13%
-0.06
+84.01%
-0.39
Purchase Of PPE
-0.18
-53.45%
-0.12
-84.13%
-0.06
+84.01%
-0.39
Sale Of PPE
—
—
0.00
0.00
Capital Expenditure
-0.18
-17.88%
-0.15
-139.68%
-0.06
+84.01%
-0.39
Net Investment Purchase And Sale
-304.93
-176.15%
-110.42
0.00
0.00
Purchase Of Investment
-451.99
-140.08%
-188.26
0.00
0.00
Sale Of Investment
147.06
+88.92%
77.84
0.00
0.00
Net Intangibles Purchase And Sale
0.00
+100.00%
-0.04
0.00
0.00
Purchase Of Intangibles
0.00
+100.00%
-0.04
0.00
0.00
Financing Cash Flow
663.23
+693.39%
83.59
+10.05%
75.96
+105.50%
36.96
Cash Flow From Continuing Financing Activities
663.23
+693.39%
83.59
+10.05%
75.96
+105.50%
36.96
Net Issuance Payments Of Debt
—
—
—
0.00
Issuance Of Debt
—
—
—
0.00
Repayment Of Debt
—
—
—
0.00
Long Term Debt Issuance
—
—
—
0.00
Long Term Debt Payments
—
—
—
0.00
Net Long Term Debt Issuance
—
—
—
0.00
Net Common Stock Issuance
182.02
+330.96%
42.24
-23.47%
55.19
+45.27%
37.99
Proceeds From Stock Option Exercised
110.84
+165.63%
41.73
+89.66%
22.00
+733266.67%
0.00
Net Other Financing Charges
370.37
+100745.11%
-0.37
+70.08%
-1.23
-19.42%
-1.03
Changes In Cash
321.14
+671.31%
-56.21
-222.04%
46.06
+83.42%
25.11
Effect Of Exchange Rate Changes
0.12
+143.49%
-0.27
-3088.89%
0.01
+102.46%
-0.37
Beginning Cash Position
31.68
-64.07%
88.16
+109.45%
42.09
+142.67%
17.34
End Cash Position
352.93
+1014.16%
31.68
-64.07%
88.16
+109.45%
42.09
Free Cash Flow
-37.17
-26.48%
-29.39
+1.72%
-29.90
-152.28%
-11.85
Interest Paid Supplemental Data
0.00
0.00
0.00
-100.00%
0.02
Income Tax Paid Supplemental Data
0.00
-100.00%
0.01
-33.33%
0.01
0.00
Common Stock Issuance
182.02
+330.96%
42.24
-23.47%
55.19
+45.27%
37.99
Issuance Of Capital Stock
182.02
+330.96%
42.24
-23.47%
55.19
+45.27%
37.99
Net Preferred Stock Issuance
—
—
—
0.00
Preferred Stock Issuance
—
—
—
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category